Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paclitaxel - Vivesto

Next Previous
X
Search
Drug Profile

Paclitaxel - Vivesto

Alternative Names: Apealea; OAS-PAC-100; Paclical; Paclitaxel micellar - Vivesto; Paclitaxel-XR-17; XR-17-paclitaxel

Latest Information Update: 13 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oasmia Pharmaceutical
  • Developer Vivesto
  • Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
  • Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No
  • Available For Licensing Yes - Fallopian tube cancer; Ovarian cancer; Peritoneal cancer

Highest Development Phases

  • Registered Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • No development reported Breast cancer

Most Recent Events

  • 07 Nov 2024 Paclitaxel - Vivesto licensed to Zhejiang Zhida Pharmaceutical in China, Hong Kong, Macau, and Taiwan .
  • 06 Mar 2024 Withdrawn for Fallopian tube cancer (Combination therapy, Second-line therapy or greater) in Denmark, Netherlands (IV), due to commercial reasons
  • 06 Mar 2024 Withdrawn for Ovarian cancer (Combination therapy, Second-line therapy or greater) in Denmark, Netherlands, Finland (IV), due to commercial reasons

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top